Cartesian Therapeutics (RNAC) Shares Outstanding (Diluted Average) (2019 - 2026)

Cartesian Therapeutics (RNAC) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $26.9 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $26.9 million, up 3.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.9 million (up 3.68% YoY), and the FY2025 annual result was $26.0 million, up 49.63% from the prior year.
• Shares Outstanding (Diluted Average) grew to $26.9 million in Q1 2026 per RNAC's latest filing, from $26.0 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $148.5 million in Q2 2022 and troughed at $5.1 million in Q1 2023.
• A 5-year average of $45.8 million and a median of $25.9 million in 2025 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) slumped 96.56% in 2023, then soared 378.44% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $145.9 million in 2022, then tumbled by 96.46% to $5.2 million in 2023, then jumped by 235.72% to $17.4 million in 2024, then surged by 49.63% to $26.0 million in 2025, then increased by 3.4% to $26.9 million in 2026.
• Business Quant data shows RNAC's Shares Outstanding (Diluted Average) at $26.9 million in Q1 2026, $26.0 million in Q4 2025, and $26.0 million in Q3 2025.